Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicinGRANDI, M; GERONI, C; GIULIANI, F. C et al.British journal of cancer. 1986, Vol 54, Num 3, pp 515-518, issn 0007-0920Article

Sequence-specific DNA alkylation of novel tallimustine derivativesMARCHINI, S; COZZI, P; BERIA, I et al.Anti-cancer drug design. 1998, Vol 13, Num 3, pp 193-205, issn 0266-9536Article

L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivativesGERONI, C; PESENTI, E; BROGGINI, M et al.British journal of cancer. 1994, Vol 69, Num 2, pp 315-319, issn 0007-0920Article

Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517) : characterization and cross-resistance studiesGERONI, C; PESENTI, E; TAGLIABUE, G et al.International journal of cancer. 1993, Vol 53, Num 2, pp 308-314, issn 0020-7136Article

Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agentsTAGLIABUE, G; PIFFERI, A; BALCONI, G et al.International journal of cancer. 1993, Vol 54, Num 3, pp 435-442, issn 0020-7136Article

Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolitesGHIELMINI, M; COLLI, E; BOSSHARD, G et al.Cancer chemotherapy and pharmacology. 1998, Vol 42, Num 3, pp 235-240, issn 0344-5704Article

Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell lineCANTONI, O; SESTILI, P; CATTABENI, F et al.Cancer chemotherapy and pharmacology. 1990, Vol 27, Num 1, pp 47-51, issn 0344-5704, 5 p.Article

Cellular and molecular pharmacology of 4'-epidoxorubicin in HeLa cells: comparison with its parent drug, doxorubicinCANTONI, O; SESTILI, P; CATTABENI, F et al.Journal of cancer research and clinical oncology. 1989, Vol 115, Num 4, pp 373-378, issn 0171-5216Article

Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicinBARBIERI, B; GIULIANI, F. C; BORDONI, T et al.Cancer research (Baltimore). 1987, Vol 47, Num 15, pp 4001-4006, issn 0008-5472Article

Cytotoxic α-bromoacrylic derivatives of distamycin analogues modified at the amidino moietyCOZZI, P; BERIA, I; CALDARELLI, M et al.Bioorganic & medicinal chemistry letters (Print). 2000, Vol 10, Num 11, pp 1273-1276, issn 0960-894XArticle

Ring-B modified anthracyclinesSUARATO, A; ANGELUCCI, F; GERONI, C et al.Current pharmaceutical design. 1999, Vol 5, Num 3, pp 217-227, issn 1381-6128Article

Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo)BELVEDERE, G; SUARATO, A; GERONI, C et al.Biochemical pharmacology. 1989, Vol 38, Num 21, pp 3713-3721, issn 0006-2952Article

Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivativesARCAMONE, F. M; ANIMATI, F; PENCO, S et al.Journal of medicinal chemistry (Print). 1989, Vol 32, Num 4, pp 774-778, issn 0022-2623, 5 p.Article

Improved synthesis and antitumor activity of 1-deazaadenosineCRISTALLI, G; FRANCHETTI, P; GRIFANTINI, M et al.Journal of medicinal chemistry (Print). 1987, Vol 30, Num 9, pp 1686-1688, issn 0022-2623Article

In vitro studies on anthracycline haloderivativesFACCHINETTI, T; GERONI, C; FUMAGALLI, A et al.Drugs under experimental and clinical research. 1986, Vol 12, Num 8, pp 657-661, issn 0378-6501Article

In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin : Role of cytochrome P450 3AQUINTIERI, L; ROSATO, A; NAPOLI, E et al.Cancer research (Baltimore). 2000, Vol 60, Num 12, pp 3232-3238, issn 0008-5472Article

α-Bromoacryloyl derivative of distamycin A (PNU 151807) : a new non-covalent minor groove DNA binder with antineoplastic activityMARCHINI, S; CIRO, M; GALLINARI, F et al.British journal of cancer. 1999, Vol 80, Num 7, pp 991-997, issn 0007-0920Article

Synthesis, cytotoxicity, antitumor activity and sequence selective binding of two pyrazole analogs structurally related to the antitumor agents U-71,184 and adozelesinBARALDI, P. G; CACCIARI, B; GERONI, C et al.Anti-cancer drug design. 1997, Vol 12, Num 7, pp 555-576, issn 0266-9536Article

Synthesis, solvolytic stability and cytotoxicity of a modified derivative of CPzI, a pyrazole analog of the alkylation subunit of the antitumor agent CC-1065 : Effect of the nitrogen substitution on the functional reactivityBARALDI, P. G; CACCIARI, B; GUIOTTO, A et al.Il Farmaco (Pavia). 1997, Vol 52, Num 12, pp 717-723, issn 0014-827XArticle

Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell linesFACCHETTI, I; GRANDI, M; CUCCHI, P et al.Anti-cancer drug design. 1991, Vol 6, Num 5, pp 385-397, issn 0266-9536Article

Studies of anthracycline-DNA complexes by circular dichroismRIZZO, V; PENCO, S; MENOZZI, M et al.Anti-cancer drug design. 1988, Vol 3, Num 2, pp 103-115, issn 0266-9536Article

Adenosine deaminase inhibitors: synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenineCRISTALLI, G; FRANCHETTI, P; GRIFANTINI, M et al.Journal of medicinal chemistry (Print). 1988, Vol 31, Num 2, pp 390-393, issn 0022-2623Article

Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin ABARALDI, P. G; ROMAGNOLI, R; BERIA, I et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 14, pp 2675-2684, issn 0022-2623Article

Novel phenyl nitrogen mustard and half-mustard derivatives of amidino-modified distamycinCOZZI, P; BERIA, I; BIASOLI, G et al.Bioorganic & medicinal chemistry letters (Print). 1997, Vol 7, Num 23, pp 2979-2984, issn 0960-894XArticle

Novel phenyl nitrogen mustard and half-mustard derivatives of distamycin ACOZZI, P; BERIA, I; MONGELLI, N et al.Bioorganic & medicinal chemistry letters (Print). 1997, Vol 7, Num 23, pp 2985-2990, issn 0960-894XArticle